MDGL
HEALTHCAREMadrigal Pharmaceuticals Inc
AI Insight
What's Moving MDGL Today?
No stock-specific AI insight has been generated for MDGL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$278.00$615.00
$519.42
Fundamentals
Market Cap$12.0B
P/E Ratio—
EPS$-13.51
Dividend Yield—
Dividend / Share—
ROE-49.3%
Profit Margin-27.3%
Debt / Equity—
Trading
Volume248K
Avg Volume (10D)—
Shares Outstanding23.1M
MDGL News
29 articles- Madrigal Pharmaceuticals Announces Grants Of Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)TradingView·Jun 22, 2026
- 3 Under-the-Radar Stocks to Buy and Hold for a DecadeMotley Fool·Jun 16, 2026
- The Bull Case For Madrigal Pharmaceuticals (MDGL) Could Change Following New Rezdiffra Cardiometabolic Data ReleaseYahoo Finance·Jun 9, 2026
- Madrigal Pharmaceuticals, Inc. Statistics – XETR:YDO1TradingView·Jun 6, 2026
- Madrigal (MDGL) Down 7.9% Since Last Earnings Report: Can It Rebound?Yahoo Finance·Jun 5, 2026
- Madrigal (MDGL) Data Highlights Rezdiffra’s Cardiometabolic Benefits for MASH Patients at EASL CongressYahoo Finance·Jun 4, 2026
- Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026Yahoo Finance·Jun 3, 2026
- Assessing Madrigal Pharmaceuticals (MDGL) Valuation After Recent Share Price WeaknessYahoo Finance·Jun 2, 2026
- Insider Sell: David Soergel Sells Shares of Madrigal PharmaceutiGuruFocus·Jun 2, 2026
- Madrigal Pharmaceuticals CMO David Soergel sells $516,561 in sharesInvesting.com·Jun 2, 2026
- Madrigal (MDGL) CMO sells 1,042 shares in 10b5-1 trade, holds 10,033Stock Titan·Jun 2, 2026
- Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%Motley Fool·May 30, 2026
- Tango Therapeutics Stock Is Up 840%, and This Fund Just Disclosed Buying $164 Million MoreMotley Fool·May 30, 2026
- Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASHYahoo Finance·May 27, 2026
- [144] MADRIGAL PHARMACEUTICALS, INC. SEC FilingStock Titan·May 22, 2026
- Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension RiskYahoo Finance·May 20, 2026
- A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Rezdiffra Blockbuster Milestone And New MASH Pipeline DealsSimply Wall Street·May 11, 2026
- A Look At Madrigal Pharmaceuticals (MDGL) Valuation After Strong Q1 2026 Earnings And Rezdiffra Sales GrowthYahoo Finance·May 10, 2026
- Madrigal Q1 Earnings Beat, MASH Drug Sales Drive Top Line, Stock UpYahoo Finance·May 7, 2026
- Madrigal Pharmaceuticals Q1 Earnings Call HighlightsMarketbeat·May 6, 2026
- Madrigal Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMoby·May 6, 2026
- Madrigal (MDGL) Q1 2026 Earnings TranscriptMotley Fool·May 6, 2026
- Madrigal’s (MDGL) MASH Strategy Reiinforced By Rezdiffra Sales Growth and Pipeline ExpansionAdvfn·May 6, 2026
- Madrigal (MDGL) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate UpdatesYahoo Finance·May 6, 2026
- Avalo shares spike on skin drug data; BioNTech to cut staffBiopharmadive·May 6, 2026
- Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026GlobeNewswire Inc.·Apr 22, 2026
- The $578 Billion Regenerative Medicine Market Has a Manufacturing Problem. One Company Just Solved the First StepBenzinga·Apr 1, 2026
- Prediction: 2 Stocks That Will Be Worth More Than Summit Therapeutics 1 Year From NowThe Motley Fool·Mar 25, 2026
All 29 articles loaded
Price Data
Open$516.83
Previous Close$513.43
Day High$527.71
Day Low$515.00
52 Week High$615.00
52 Week Low$278.00
52-Week Range
$278.00$615.00
$519.42
Fundamentals
Market Cap$12.0B
P/E Ratio—
EPS$-13.51
Dividend Yield—
Dividend / Share—
ROE-49.3%
Profit Margin-27.3%
Debt / Equity—
Trading
Volume248K
Avg Volume (10D)—
Shares Outstanding23.1M
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic and liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeCommon Stock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—